Cargando…

Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF-κB signaling pathways

Atherosclerosis (AS) is an inflammatory disease that occurs in the arterial wall and is characterized by progressive lipid accumulation within the intima of large arteries, leading to the dysfunction of endothelial cells and further destruction of the endothelial barrier and vascular tone. Arterial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pang, Jianliang, Hu, Peiyang, Wang, Junwei, Jiang, Jinsong, Lai, Jifu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522885/ https://www.ncbi.nlm.nih.gov/pubmed/31059055 http://dx.doi.org/10.3892/mmr.2019.10211

Ejemplares similares

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

TLRs, NF-κB, JNK, and Liver Regeneration
por: Iimuro, Yuji, et al.
Publicado: (2010)

Barrier stabilizing mediators in regulation of microvascular endothelial permeability
por: Qiao-bing, Huang, et al.
Publicado: (2012)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
por: Cheng, Judy WM
Publicado: (2016)

NF-κB, JNK, and TLR Signaling Pathways in Hepatocarcinogenesis
por: Maeda, Shin
Publicado: (2010)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

Holey barrier: claudins and the regulation of brain endothelial permeability
por: Matter, Karl, et al.
Publicado: (2003)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
por: Farag, Mohamed, et al.
Publicado: (2015)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML
por: Volk, Andrew, et al.
Publicado: (2014)

Human Adenoviruses, Cholesterol Trafficking, and NF-κB Signaling
por: Cianciola, Nicholas L., et al.
Publicado: (2018)

Endotoxin-activated microglia injure brain derived endothelial cells via NF-κB, JAK-STAT and JNK stress kinase pathways
por: Kacimi, Rachid, et al.
Publicado: (2011)

JNK‐IN‐8 treatment improves ARDS‐induced cognitive impairment by inhibiting JNK/NF‐κB‐mediated NLRP3 inflammasome
por: Shi, Yunchao, et al.
Publicado: (2023)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Asef controls vascular endothelial permeability and barrier recovery in the lung
por: Tian, Xinyong, et al.
Publicado: (2015)

Permeability of Epithelial/Endothelial Barriers in Transwells and Microfluidic Bilayer Devices
por: Frost, Timothy S., et al.
Publicado: (2019)

Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and the inflammatory cascade by modulating the PI3K/Akt and JNK/NF-κB pathways
por: Hao, Liangliang, et al.
Publicado: (2022)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
por: van Diepen, Sean, et al.
Publicado: (2015)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation
por: Ku, Yun Hyi, et al.
Publicado: (2017)

Protective Effect of Oligonol on Dimethylnitrosamine-Induced Liver Fibrosis in Rats via the JNK/NF-κB and PI3K/Akt/Nrf2 Signaling Pathways
por: Lee, Changyong, et al.
Publicado: (2021)

Melatonin protects blood-brain barrier integrity and permeability by inhibiting matrix metalloproteinase-9 via the NOTCH3/NF-κB pathway
por: Qin, Weiwei, et al.
Publicado: (2019)

TNF-α Signals Through PKCζ/NF-κB to Alter the Tight Junction Complex and Increase Retinal Endothelial Cell Permeability
por: Aveleira, Célia A., et al.
Publicado: (2010)

Salusin-β, but Not Salusin-α, Promotes Human Umbilical Vein Endothelial Cell Inflammation via the p38 MAPK/JNK-NF-κB Pathway
por: Zhou, Cheng-Hua, et al.
Publicado: (2014)

The Synergistic Repressive Effect of NF-κB and JNK Inhibitor on the Clonogenic Capacity of Jurkat Leukemia Cells
por: Liu, Xinli, et al.
Publicado: (2014)

Sulfated Chitosan Oligosaccharides Suppress LPS-Induced NO Production via JNK and NF-κB Inactivation
por: Kim, Jung-Hyun, et al.
Publicado: (2014)

Targeting GPR65 alleviates hepatic inflammation and fibrosis by suppressing the JNK and NF-κB pathways
por: Zhang, Kun, et al.
Publicado: (2023)

Cholesterol restricts lymphotoxin β receptor-triggered NF-κB signaling
por: Banach-Orłowska, Magdalena, et al.
Publicado: (2019)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

JNK-IN-8 treatment alleviates lipopolysaccharide-induced acute lung injury via suppression of inflammation and oxidative stress regulated by JNK/NF-κB signaling
por: Du, Jingxian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bglomdia9o3p91ccv9auufoj9n